Church & Dwight, founded in 1846, is the leading U.S. producer of baking soda. Headquartered in Ewing, New Jersey, the company manufactures and markets personal care, household, and specialty products and has 14 'power brands' that represent over 80% of its revenue. Its brands include Arm & Hammer, Trojan, Oxiclean, Spinbrush, First Response, Nair, Oragel, Xtra, L'il Critters, Vitafusion, Batiste, Waterpik, Flawless, and Zicam. The company has approximately 5,550 employees.

The stock market stalled last week after an impressive run that saw the S&P 500 bolt from 4982 in late April to 5659 at the close on Friday. Insider sentiment moved mostly in lock-step with that surge, though the insider-sentiment data from Vickers Stock Research turned bullish during the week of April 7, ahead of the market's bullish run. Last week, insider-sentiment again mirrored the broader market by 'stalling' but not fading. On a scale where sentiment is bullish under 2.00 and neutral from 2.00 to 6.00, the NYSE Eight-Week Sell/Buy Ratio from Vickers is now 2.01 versus 1.83 last week, representing a slight fallback. For the Nasdaq, there was some improvement, with the Nasdaq Eight-Week Sell/Buy Ratio at 2.87 this week versus 2.98 last week. Putting all the data together, Vickers' Total (all exchanges) Eight-Week Sell/Buy Ratio is currently 2.39, essentially unchanged from 2.34 last week. So insider sentiment stalled, but in a pretty positive place. Insider selling outpaced insider buying across all sectors over the last week, but insider buying in the Consumer Discretionary sector lagged selling by a factor of just 2.0-times. Selling was the greatest in Consumer Staples over the last week, with shares valued at $111 million sold versus just $2 million bought. Selling was also notable in Financials, with shares valued at $99 million sold versus just $5 million bought, as well as Healthcare, where insiders sold shares valued at $97 million versus $7 million bought. This week, analysts at Vickers highlighted insider transactions of interest at CrowdStrike Holdings Inc. (NGS: CRWD) and GoDaddy Inc. (NYSE: GDDY).

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

RESMED INC has an Investment Rating of HOLD; a target price of $225.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.